Cargando…

EBV-IgA antibody responses in endemic and nonendemic populations with nasopharyngeal carcinoma: tumour marker prognostication study and a cross-sectional study

Nasopharyngeal carcinoma (NPC) is the most prevalent head and neck cancer in Indonesia, with 100% Epstein–Barr virus (EBV) infection in tumor cells. NPC is rare in the Netherlands. The involvement of EBV in NPC pathogenesis is reflected by early onset aberrant IgA antibody responses to various EBV p...

Descripción completa

Detalles Bibliográficos
Autores principales: Budiningsih, Insani, Verkuijlen, Sandra A.W.M., Dachlan, Yoes P., Arfijanto, Muhammad V., Hadi, Usman, Middeldorp, Jaap M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10473314/
https://www.ncbi.nlm.nih.gov/pubmed/37663720
http://dx.doi.org/10.1097/MS9.0000000000000963
_version_ 1785100249815056384
author Budiningsih, Insani
Verkuijlen, Sandra A.W.M.
Dachlan, Yoes P.
Arfijanto, Muhammad V.
Hadi, Usman
Middeldorp, Jaap M.
author_facet Budiningsih, Insani
Verkuijlen, Sandra A.W.M.
Dachlan, Yoes P.
Arfijanto, Muhammad V.
Hadi, Usman
Middeldorp, Jaap M.
author_sort Budiningsih, Insani
collection PubMed
description Nasopharyngeal carcinoma (NPC) is the most prevalent head and neck cancer in Indonesia, with 100% Epstein–Barr virus (EBV) infection in tumor cells. NPC is rare in the Netherlands. The involvement of EBV in NPC pathogenesis is reflected by early onset aberrant IgA antibody responses to various EBV proteins. Screening for elevated EBV-IgA levels is proposed for NPC risk assessment in endemic countries but is poorly studied in nonendemic regions. This study analyzed the overall diversity (immunoblot) as well as the prevalence and normalized levels of IgA responses to immunodominant peptide epitopes of EBV proteins VCA P18, EBNA 1, and Zebra (Zta) (N-terminus, P 125, P 130, full-length recombinant Zebra) in Indonesian (n=50) and Dutch (n=50) patients with NPC. The results confirmed that elevated levels of IgA-VCA P18 and IgA-EBNA 1 were found in both NPC populations, but that IgA-Zta was more variable. IgA-Zta responses were more pronounced in Indonesian NPC cases, reflecting more frequent EBV reactivation overall. IgA-VCA P18 and IgA-EBNA are independent tumor markers and are both necessary for NPC risk assessment. Overall, these results confirmed the diagnostic benefit of combined IgA-VCA P18/-EBNA 1 testing for NPC risk assessment in endemic and nonendemic populations.
format Online
Article
Text
id pubmed-10473314
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-104733142023-09-02 EBV-IgA antibody responses in endemic and nonendemic populations with nasopharyngeal carcinoma: tumour marker prognostication study and a cross-sectional study Budiningsih, Insani Verkuijlen, Sandra A.W.M. Dachlan, Yoes P. Arfijanto, Muhammad V. Hadi, Usman Middeldorp, Jaap M. Ann Med Surg (Lond) Original Research Nasopharyngeal carcinoma (NPC) is the most prevalent head and neck cancer in Indonesia, with 100% Epstein–Barr virus (EBV) infection in tumor cells. NPC is rare in the Netherlands. The involvement of EBV in NPC pathogenesis is reflected by early onset aberrant IgA antibody responses to various EBV proteins. Screening for elevated EBV-IgA levels is proposed for NPC risk assessment in endemic countries but is poorly studied in nonendemic regions. This study analyzed the overall diversity (immunoblot) as well as the prevalence and normalized levels of IgA responses to immunodominant peptide epitopes of EBV proteins VCA P18, EBNA 1, and Zebra (Zta) (N-terminus, P 125, P 130, full-length recombinant Zebra) in Indonesian (n=50) and Dutch (n=50) patients with NPC. The results confirmed that elevated levels of IgA-VCA P18 and IgA-EBNA 1 were found in both NPC populations, but that IgA-Zta was more variable. IgA-Zta responses were more pronounced in Indonesian NPC cases, reflecting more frequent EBV reactivation overall. IgA-VCA P18 and IgA-EBNA are independent tumor markers and are both necessary for NPC risk assessment. Overall, these results confirmed the diagnostic benefit of combined IgA-VCA P18/-EBNA 1 testing for NPC risk assessment in endemic and nonendemic populations. Lippincott Williams & Wilkins 2023-07-19 /pmc/articles/PMC10473314/ /pubmed/37663720 http://dx.doi.org/10.1097/MS9.0000000000000963 Text en Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/)
spellingShingle Original Research
Budiningsih, Insani
Verkuijlen, Sandra A.W.M.
Dachlan, Yoes P.
Arfijanto, Muhammad V.
Hadi, Usman
Middeldorp, Jaap M.
EBV-IgA antibody responses in endemic and nonendemic populations with nasopharyngeal carcinoma: tumour marker prognostication study and a cross-sectional study
title EBV-IgA antibody responses in endemic and nonendemic populations with nasopharyngeal carcinoma: tumour marker prognostication study and a cross-sectional study
title_full EBV-IgA antibody responses in endemic and nonendemic populations with nasopharyngeal carcinoma: tumour marker prognostication study and a cross-sectional study
title_fullStr EBV-IgA antibody responses in endemic and nonendemic populations with nasopharyngeal carcinoma: tumour marker prognostication study and a cross-sectional study
title_full_unstemmed EBV-IgA antibody responses in endemic and nonendemic populations with nasopharyngeal carcinoma: tumour marker prognostication study and a cross-sectional study
title_short EBV-IgA antibody responses in endemic and nonendemic populations with nasopharyngeal carcinoma: tumour marker prognostication study and a cross-sectional study
title_sort ebv-iga antibody responses in endemic and nonendemic populations with nasopharyngeal carcinoma: tumour marker prognostication study and a cross-sectional study
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10473314/
https://www.ncbi.nlm.nih.gov/pubmed/37663720
http://dx.doi.org/10.1097/MS9.0000000000000963
work_keys_str_mv AT budiningsihinsani ebvigaantibodyresponsesinendemicandnonendemicpopulationswithnasopharyngealcarcinomatumourmarkerprognosticationstudyandacrosssectionalstudy
AT verkuijlensandraawm ebvigaantibodyresponsesinendemicandnonendemicpopulationswithnasopharyngealcarcinomatumourmarkerprognosticationstudyandacrosssectionalstudy
AT dachlanyoesp ebvigaantibodyresponsesinendemicandnonendemicpopulationswithnasopharyngealcarcinomatumourmarkerprognosticationstudyandacrosssectionalstudy
AT arfijantomuhammadv ebvigaantibodyresponsesinendemicandnonendemicpopulationswithnasopharyngealcarcinomatumourmarkerprognosticationstudyandacrosssectionalstudy
AT hadiusman ebvigaantibodyresponsesinendemicandnonendemicpopulationswithnasopharyngealcarcinomatumourmarkerprognosticationstudyandacrosssectionalstudy
AT middeldorpjaapm ebvigaantibodyresponsesinendemicandnonendemicpopulationswithnasopharyngealcarcinomatumourmarkerprognosticationstudyandacrosssectionalstudy